Study on Bisoprolol for Chagas Cardiomyopathy
Author Information
Author(s): Quiros Franklin R, Morillo Carlos A, Casas Juan P, Cubillos Luz A, Silva Federico A
Primary Institution: Fundación Cardiovascular de Colombia
Hypothesis
Bisoprolol will reduce cardiovascular death in patients with Chagas' cardiomyopathy with heart failure functional class NYHA II to IV.
Conclusion
The study aims to evaluate the effects of Bisoprolol on cardiovascular mortality and hospital readmission in patients with Chagas cardiomyopathy.
Supporting Evidence
- Chagas' disease is a major cause of disability in Latin America.
- Beta-blockers have shown benefits in heart failure patients.
- Bisoprolol has been effective in improving outcomes in heart failure.
Takeaway
This study is testing if a heart medicine called Bisoprolol can help people with a serious heart problem caused by a disease called Chagas.
Methodology
A randomized double-blind placebo-controlled trial with 500 T. cruzi seropositive patients, assessing the effects of Bisoprolol on heart failure outcomes.
Potential Biases
Potential biases related to patient selection and adherence to treatment protocols.
Limitations
The study may not generalize to all populations with Chagas disease due to specific inclusion criteria.
Participant Demographics
Males and females aged 18 to 70 years with heart failure symptoms NYHA functional class II to IV.
Statistical Information
P-Value
p < 0.001 for total all-cause mortality reduction.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website